TW200306184A - Heterocyclic amide derivatives for the treatment of diabetes and other diseases - Google Patents

Heterocyclic amide derivatives for the treatment of diabetes and other diseases Download PDF

Info

Publication number
TW200306184A
TW200306184A TW092105025A TW92105025A TW200306184A TW 200306184 A TW200306184 A TW 200306184A TW 092105025 A TW092105025 A TW 092105025A TW 92105025 A TW92105025 A TW 92105025A TW 200306184 A TW200306184 A TW 200306184A
Authority
TW
Taiwan
Prior art keywords
group
compound
carbon atoms
item
substituted
Prior art date
Application number
TW092105025A
Other languages
English (en)
Chinese (zh)
Inventor
Magnus Pfahl
Catherine Tachdjian
Hussien A Al-Shamma
Andrea Fanjul Giachino
Karine Jakubowicz-Jaillardon
Guo Jianhua
Boudjelal Mohamed
W Zapf James
Original Assignee
Incyte San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte San Diego Inc filed Critical Incyte San Diego Inc
Publication of TW200306184A publication Critical patent/TW200306184A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092105025A 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases TW200306184A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36270202P 2002-03-08 2002-03-08

Publications (1)

Publication Number Publication Date
TW200306184A true TW200306184A (en) 2003-11-16

Family

ID=27805215

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092105025A TW200306184A (en) 2002-03-08 2003-03-07 Heterocyclic amide derivatives for the treatment of diabetes and other diseases

Country Status (14)

Country Link
US (2) US7102000B2 (cg-RX-API-DMAC7.html)
EP (1) EP1487443A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005530705A (cg-RX-API-DMAC7.html)
KR (1) KR20050006126A (cg-RX-API-DMAC7.html)
CN (1) CN1649586A (cg-RX-API-DMAC7.html)
AU (1) AU2003225682A1 (cg-RX-API-DMAC7.html)
CA (1) CA2478342A1 (cg-RX-API-DMAC7.html)
IL (1) IL163952A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04008733A (cg-RX-API-DMAC7.html)
NO (1) NO20044250L (cg-RX-API-DMAC7.html)
RU (1) RU2004129752A (cg-RX-API-DMAC7.html)
TW (1) TW200306184A (cg-RX-API-DMAC7.html)
WO (1) WO2003075924A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200408057B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1384825A (zh) * 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
BR0207846A (pt) * 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) * 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Rxr活性化分子
EP1421061A4 (en) * 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
US7196108B2 (en) * 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
BRPI0409501A (pt) * 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE602005020646D1 (de) * 2004-08-30 2010-05-27 Takeda Pharmaceutical Screening-verfahren
CN101316821A (zh) 2005-09-30 2008-12-03 詹森药业有限公司 作为rxr激动剂用于治疗异常脂肪血症、高胆固醇血症和糖尿病的二氢-[1h]-喹啉-2-酮衍生物
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
WO2012153775A1 (ja) 2011-05-10 2012-11-15 国立大学法人神戸大学 Ras機能阻害作用を有するチオキソチアゾリジン誘導体
EP3062819B1 (en) 2013-11-03 2021-12-22 The Regents of The University of California Ionic liquids for transdermal drug delivery
EP3467459B1 (en) * 2016-06-07 2020-11-25 Mitsubishi Electric Corporation Temperature estimation method
US10912834B2 (en) 2016-08-29 2021-02-09 The Regents Of The University Of California Topical formulations based on ionic species for skin treatment
US10828265B2 (en) 2016-12-09 2020-11-10 The Regents Of The University Of California Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
JPS63230689A (ja) * 1987-03-18 1988-09-27 Tanabe Seiyaku Co Ltd ベンゾオキサジン誘導体
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
EP0595868B1 (en) 1991-07-22 1998-11-25 Pfizer Inc. Process for the preparation of (s)-4-[3-(5-methyl-2-phenyl-4-oxazolyl)- 1-hydroxypropyl]bromobenzene
DE69333894D1 (de) 1992-04-22 2005-12-01 Ligand Pharm Inc Verbindungen mit Retinoid x rezeptorselektivität
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
WO1994012880A2 (en) 1992-11-25 1994-06-09 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
ES2130597T3 (es) 1994-02-17 1999-07-01 American Home Prod Derivados de bifenilo sustituido como inhibidores de la fosfodiesterasa.
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
CA2223489A1 (en) 1995-07-17 1997-02-06 Joseph A. Fontana Method for treating cancer using ahpn
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
WO1997027191A1 (en) 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation
US6127415A (en) 1996-07-08 2000-10-03 Galderma Research & Development, S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
CA2300813A1 (en) 1997-08-21 1999-03-04 Hiroyuki Odaka Anti-inflammatory agent
EP1048659A4 (en) 1997-11-12 2002-11-20 Inst Med Molecular Design Inc Retinoid receptor Antagonist
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
IL141456A0 (en) 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
WO2000018748A1 (en) 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU3111700A (en) 1998-12-04 2000-06-19 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
CN1384825A (zh) 1999-08-31 2002-12-11 马克西亚药品公司 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用
PT1142885E (pt) 1999-11-12 2007-02-28 Fujimoto Brothers Co Ltd Derivados de 2-(n-cianoimino)tiazolidin-4-ona
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
BR0207846A (pt) 2001-03-07 2005-09-13 Incyte San Diego Inc Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Rxr活性化分子
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−x受容体モジュレーターを含んで成る併用療法
EP1421061A4 (en) 2001-08-17 2004-12-22 Incyte San Diego Inc OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEROLEMIA
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US20050014767A1 (en) 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
BRPI0409501A (pt) 2003-04-18 2006-04-18 Incyte San Diego Inc compostos isocromanos substituìdos para o tratamento de desordens metabólicas, de cáncer e de outras doenças

Also Published As

Publication number Publication date
CN1649586A (zh) 2005-08-03
NO20044250L (no) 2004-11-03
EP1487443A4 (en) 2006-04-12
EP1487443A1 (en) 2004-12-22
KR20050006126A (ko) 2005-01-15
IL163952A0 (en) 2005-12-18
US20030216432A1 (en) 2003-11-20
CA2478342A1 (en) 2003-09-18
US7102000B2 (en) 2006-09-05
US20060241138A1 (en) 2006-10-26
JP2005530705A (ja) 2005-10-13
MXPA04008733A (es) 2006-07-03
AU2003225682A2 (en) 2003-09-22
ZA200408057B (en) 2007-05-30
RU2004129752A (ru) 2005-05-10
AU2003225682A1 (en) 2003-09-22
WO2003075924A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
ES2248107T3 (es) Benciliden-tiazolidindionas y analogos y su utilizacion en el tratamiento de la diabetes.
TWI277415B (en) Bicyclic heterocycles for the treatment of diabetes and other diseases
CN115244056A (zh) 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2006046593A1 (ja) 2以上の置換基を有するベンゼン化合物
US7102000B2 (en) Heterocyclic amide derivatives for the treatment of diabetes and other diseases
HUT57752A (en) Process for producing thiazole derivatives and pharmaceutical compositions comprising same
WO2008066097A1 (fr) Dérivé d'acide carboxylique
WO2008016175A1 (en) Activator for peroxisome proliferator activated receptor
KR20150079968A (ko) 헤테로아릴 유도체 및 그의 용도
CN107108525A (zh) 用作Lp‑PLA2抑制剂的嘧啶酮类化合物及其药物组合物
KR20220143062A (ko) 신규 ep4 길항제의 합성 및 암과 염증에서의 이의 용도
TW200530223A (en) Heteroaryl derivatives as PPAR activators
JP2006523724A (ja) 代謝障害、癌および他の疾患の治療のための置換イソクロマン化合物
WO2006109633A1 (ja) 置換インドール化合物
JP2013538870A (ja) 新規gpr119アゴニスト
WO2022233302A1 (zh) 嘧啶酮衍生物、其制备方法、药物组合物和用途
JPS61100579A (ja) ピリジン誘導体
JP2007509039A (ja) シクロペンテン化合物
WO2007004733A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
KR102406246B1 (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도
JP3985121B2 (ja) ジヒドロキノリン誘導体
JP2009503007A (ja) フェニルピリジン誘導体、それらの製造、及び医薬品としての使用
EP1593677A2 (en) Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes
WO2026041115A1 (zh) 作为蛋白质酪氨酸磷酸酶抑制剂的含双键取代的化合物及其应用
WO2003078422A1 (en) Novel pyridone derivative